Ironwood Pharmaceuticals

Regulatory Delays And Pricing Headwinds Will Impede Performance But Stabilize

AnalystLowTarget

Not Invested

Community Contributor

Published

16 May 25

AnalystLowTarget's Fair Value

US$0.70

130.0% overvalued

16 Jul

US$1.61

-61.9%

26.8%

-61.9%

26.8%

You can edit this narrative until May 16 10:06 PM. Then, changes will post as Updates.

Author's Valuation

US$0.7130.0% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$0.7

130.0% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

-14.91%

Biotech revenue growth rate

8.32%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

11.03%

Calculation

US$17.49m

Earnings '28

9.35x

PE Ratio '28

US$163.46m

Market Cap '28

US$163.46m

Market Cap '28

168.23m

No. shares '28

US$0.97

Share Price '28

US$0.97 Share Price '28

Discounted to 2025 @ 11.60% p.a.

US$0.70

Fair Value '25